Perspective Therapeutics Earns Buy Rating as Justin Walsh Reaffirms $18 Price Target on Strength of Pb-212 Pipeline and Upcoming Phase III ProgramTip Ranks·Aug 14 at 10:25 AMCATX-2.20%
Perspective Therapeutics (CATX) Receives a Hold from Bank of America SecuritiesTip Ranks·Aug 14 at 06:45 AMCATX-2.20%
Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATXMarket Beat·Aug 14 at 02:36 AMCATX-2.20%JPM+0.96%
Wedbush Sticks to Their Buy Rating for Perspective Therapeutics (CATX)Tip Ranks·Aug 11 at 09:57 AMCATX-2.20%
Perspective Therapeutics | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 81 KEarnings Watch·Aug 10 at 04:09 PMCATX-2.20%
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results | CATX Stock NewsStockTitan·Aug 10 at 07:22 AMCATX-2.20%
Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LPMarket Beat·Aug 1 at 02:40 AMCATX-2.20%
Perspective Therapeutics to report Q2 2026 results after market closePUBT·Jul 31 at 05:30 AMCATX-2.20%
1,055,409 Shares in Perspective Therapeutics, Inc. $CATX Bought by Yu FanMarket Beat·Jul 29 at 05:48 AMCATX-2.20%DB+0.72%
Perspective Therapeutics wins EU orphan drug status for (212Pb) VMT-α-NET in GEP-NETsPUBT·Jul 28 at 05:35 AMCATX-2.20%
